ViewRay Reports Fourth Quarter and Full Year 2018 Results
CLEVELAND, March 14, 2019 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2018.
Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.
Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.
ViewRay Reports Fourth Quarter and Full Year 2018 Results
CLEVELAND, March 14, 2019 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2018.
MRI-Guided Radiation: A New Option for Pancreatic Cancer Treatment
Let's Win! Pancreatic Cancer / Lustgarten Foundation: Researchers will enroll 133 patients with borderline resectable or inoperable locally advanced pancreatic cancer in a new, five-year Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) trial.
ViewRay, Inc. (Nasdaq: VRAY), announced today that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market new soft tissue visualization capabilities for its MRIdian system.
A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.
Contact Us Today To Learn More Contact
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy